MEDIPURE ANNOUNCES APPOINTMENT OF RENOWNED CROATIAN HEALTH SPECIALIST

Vancouver, BC – February,  2019 - Medipure Holdings Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Dr. Ognjen Brborović to its Scientific Advisory Board.

Dr. Brborović is one of Croatia’s most prominent professionals in pharmaco-economics, having authored more than 20-scientific papers published in peer reviewed journals, in addition to completing more than 100-studies for some of the world’s biggest pharmaceutical companies.

“We are very happy to have Dr. Brborović join our expanding team of experts at Medipure," said Boris Weiss, CEO of Medipure. "With more than a decade of experience in the field of pharmaco-economics and drug market access, he will be a valuable addition to our revolutionary team, including our Croatian subsidiary and potential partners in the European Union.“

In August, Medipure announced the creation of a subsidiary, Medipure d.o.o., in Croatia through which R&D will focus on clinical trials and pharmacology. Along with full analytical labs, this site will house a GMP facility allowing the Company to produce drugs in compliance with the European regulatory standards necessary to support clinical trials on the road to regulatory approvals and commercialization.

Dr. Brborović graduated from the University of Zagreb School of Medicine in 1998 and also holds a Ph.D. in Biomedical Sciences. He has served as Vice President of the Croatian Public Health Society. He currently works in the Department of Social Medicine and Healthcare Organization, School of Medicine, University of Zagreb.

For more information, please visit: http://medipurepharmaceuticals.com

 

ABOUT MEDIPURE
Medipure is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis, dermatology and fatty liver disease (NASH). Medipure's  research and development is focused on having the greatest impact and benefit for patients worldwide. At the same time, we aim to make sure that our products are approved by regulators and well understood by physicians, healthcare providers and prospective patients.